PharmaCorp Announces Upsized C$20 Million Bought Deal Public Offering

Core Viewpoint - PharmaCorp Rx Inc. has announced a bought deal offering of 47.7 million units at C$0.42 per unit, aiming to raise C$20.0 million due to strong investor demand [1][3] Group 1: Offering Details - The offering consists of units, each comprising one common share and one-half of a common share purchase warrant, with the warrant allowing the purchase of one common share at C$0.50 for 24 months [2] - The closing of the offering is expected around November 12, 2025, pending regulatory approvals [3] - An over-allotment option allows underwriters to purchase an additional 15% of the units sold to cover over-allotments [4] Group 2: Use of Proceeds - The net proceeds from the offering will be allocated for future acquisition opportunities and general working capital [3] Group 3: Company Overview - PharmaCorp is focused on acquiring and operating community pharmacies in Canada, empowering pharmacists as equity partners [7] - The company operates seven pharmacies under the PharmaChoice Canada banner and plans to continue acquiring both bannered and independent pharmacies [8]